At CIIE, Lecheng steps up cooperation with leading medical firms

During the ongoing 6th China International Import Expo (CIIE)—while conducting exchanges with over 30 well-known medical device companies from China and around the world—the Hainan Boao Lecheng International Medical Tourism Pilot Zone has signed a raft of agreements.

The Hainan Institute of Real World Data (part of the Lecheng pilot zone) signed a strategic agreement with Pfizer China, a subsidiary of the American multinational pharmaceutical and biotechnology corporation. The company has brought eight innovative medications to Lecheng since 2020, with the first one—Lorlatinib—approved as a treatment for ALK-positive lung cancer.

According to Pfizer China Vice President and Chief Medical Officer Felix Cao, by leveraging the pilot zone's preferential policies, the company will—to improve scientific research and clinical treatment—promote the cooperation with Lecheng in terms of real world data.

The CIIE also witnessed a tripartite agreement reached among the administration of Lecheng, West China Medical Center Lecheng Hospital, and Gilead Sciences (an American biopharmaceutical company). The three parties will work together to develop a cutting-edge medical center able to satisfy multi-level clinical and scientific demands.

During this year’s CIIE, Johnson & Johnson Vision's ELITA Femtosecond Laser System announced that Lecheng would be a demonstration base. Soon, the latest femtosecond laser technology for the treatment of refractive correction on patients with myopia will be available in the Boao Lecheng Aier Eye Hospital.

The fruitful results Lecheng achieved during the expo also include agreements with Amgen (one of the world's leading biotechnology companies) and Allergan Aesthetics (a global leader in facial aesthetics), and exploring more international collaborations in many medical fields.

One of the 13 key industrial parks in south China’s Hainan Free Trade Port, Lecheng is a pilot zone bringing in advanced drugs and medical devices from overseas, and a key channel to accelerate the market entry of innovative international pharmaceutical products into China. To date, more than 350 critically-needed pharmaceutical products have been made available in Lecheng.